Thomas Kindler

7.2k total citations
78 papers, 3.0k citations indexed

About

Thomas Kindler is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Thomas Kindler has authored 78 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 34 papers in Molecular Biology and 26 papers in Genetics. Recurrent topics in Thomas Kindler's work include Chronic Myeloid Leukemia Treatments (31 papers), Acute Myeloid Leukemia Research (29 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers). Thomas Kindler is often cited by papers focused on Chronic Myeloid Leukemia Treatments (31 papers), Acute Myeloid Leukemia Research (29 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers). Thomas Kindler collaborates with scholars based in Germany, United States and United Kingdom. Thomas Kindler's co-authors include Thomas Fischer, Daniel B. Lipka, Bernd Kaina, Daniel Heylmann, Franz Rödel, Frank Breitenbuecher, Thomas Fischer, Christian Brandts, Hubert Serve and Stefan Kasper and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Thomas Kindler

74 papers receiving 2.9k citations

Peers

Countries citing papers authored by Thomas Kindler

Since Specialization

Citations

This map shows the geographic impact of Thomas Kindler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Kindler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Kindler more than expected).

Fields of papers citing papers by Thomas Kindler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Kindler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Kindler. The network helps show where Thomas Kindler may publish in the future.

Co-authorship network of co-authors of Thomas Kindler

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Kindler. A scholar is included among the top collaborators of Thomas Kindler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Kindler. Thomas Kindler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Chimeric Antigen Receptor T Cell Target Claudin 6 Is a Marker for Early Organ-Specific Epithelial Progenitors and Is Expressed in Some Pediatric Solid Tumor Entities 2025 ·Cancers ·Larissa Seidmann, Arthur Wingerter, Marie Oliver Metzig, (unknown), Khalifa El Malki, (unknown), (unknown), (unknown), Thomas Kindler, Mark Laible, (unknown), Nicole Henninger, Alexandra Russo, Olaf Beck, Francesca Alt, (unknown), Wilfried Roth, Claudia Paret, Joerg Faber	0
2	198P Inavolisib in cancers with activating PIK3CA mutations: Results from the CRAFT trial 2024 ·Annals of Oncology ·Christoph E. Heilig, (unknown), Alexander Desuki, Thomas Kindler, Barbara Deschler-Baier, (unknown), Nikolas von Bubnoff, (unknown), Damian Rieke, (unknown), (unknown), Simon Kreutzfeldt, Peter Horak, Karen Steindorf, Axel Benner, Daniel Hübschmann, Nina Schweigert, (unknown), Stefan Fröhling, Richard F. Schlenk	1
3	1940P Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials 2023 ·Annals of Oncology ·Richard F. Schlenk, Małgorzata Oleś, Sebastian Bauer, Thomas Kindler, Frederick Klauschen, Christian Brandts, Damian Rieke, (unknown), Melanie Börries, Christoph Heining, Peter Horak, Michael Bitzer, Uta Dirksen, Monika Sparber‐Sauer, (unknown), Simon Kreutzfeldt, Hanno Glimm, Daniel Hübschmann, Christoph E. Heilig, Stefan Fröhling	0
4	2318P Value of broad molecular profiling for cancer diagnosis 2023 ·Annals of Oncology ·(unknown), Christoph E. Heilig, (unknown), Jennifer Hüllein, Mandeep Singh, Sebastian Bauer, Thomas Kindler, Frederick Klauschen, Christian Brandts, Damian Rieke, (unknown), Melanie Börries, Simon Kreutzfeldt, Peter Horak, Daniel Hübschmann, Daniel B. Lipka, Hanno Glimm, Wolfgang Hartmann, Stefan Fröhling	1
5	Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3 2021 ·Archives of Toxicology ·(unknown), (unknown), (unknown), (unknown), Mandy Beyer, (unknown), Andrea Piée‐Staffa, (unknown), (unknown), Andreas Sellmer, Siavosh Mahboobi, Thomas Kindler, Walburgis Brenner, Teodora Nikolova, Oliver H. Krämer	19
6	Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells 2021 ·Cell chemical biology ·Mandy Beyer, (unknown), (unknown), (unknown), (unknown), (unknown), Markus Christmann, Andreas Sellmer, Siavosh Mahboobi, Sebastian Drube, Wolfgang Sippl, Thomas Kindler, Oliver H. Krämer	18
7	cbpManager: a web application to streamline the integration of clinical and genomic data in cBioPortal to support the Molecular Tumor Board 2021 ·BMC Medical Informatics and Decision Making ·(unknown), Alexander Desuki, (unknown), (unknown), Daniel‐Christoph Wagner, Jan Christoph, (unknown), Thomas Kindler, Jörg Faber, Fédérico Marini, (unknown), Claudia Paret	5
8	Distinct immune evasion in APOBEC ‐enriched, HPV ‐negative HNSCC 2020 ·International Journal of Cancer ·(unknown), Benedikt Obermayer, Konrad Klinghammer, Sebastian Ochsenreither, Denise Treue, Albrecht Stenzinger, Hanno Glimm, Stefan Fröhling, Thomas Kindler, Christian Brandts, Klaus Schulze‐Osthoff, Wilko Weichert, Ingeborg Tinhofer, Frederick Klauschen, Ulrich Keilholz, Dieter Beule, Damian Rieke	12
9	Spatial Chromosome Folding and Active Transcription Drive DNA Fragility and Formation of Oncogenic MLL Translocations 2019 ·Molecular Cell ·Henrike Johanna Gothe, Britta A. M. Bouwman, Eduardo Gade Gusmao, (unknown), Giuseppe Petrosino, Sergi Sayols, Oliver Drechsel, Vera Minneker, Nataša Josipović, Athanasia Mizi, Christian Friberg Nielsen, (unknown), Shunichi Takeda, Hiroyuki Sasanuma, Damien F. Hudson, Thomas Kindler, Laura Baranello, Argyris Papantonis, Nicola Crosetto, Vassilis Roukos	96
10	COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110) 2017 ·Haematologica ·Frank Stegelmann, Martin Grießhammer, Markus Bangerter, Holger Hebart, (unknown), (unknown), Nikolas von Bubnoff, Christof Scheid, (unknown), Steffen Koschmieder, Konstanze Doehner, Thomas Kindler, Andreas Reiter, Denise Wolleschak, Andreas Hochhaus, Florian H. Heidel, (unknown), Hartmut Doehner	2
11	Paraoxonase-2 alters hematopoietic stem cell differentiation through redox signalling 2017 ·Experimental Hematology ·(unknown), Thomas Kindler, Sven Horke, Ines Witte	1
12	Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF) 2015 ·Blood ·Claire Harrison, Jean‐Jacques Kiladjian, Florian H. Heidel, Alessandro M. Vannucchi, Francesco Passamonti, (unknown), Eibhlin Conneally, Bruno Martino, Thomas Kindler, Daniel B. Lipka, Suddhasatta Acharyya, Prashanth Gopalakrishna, Susan Ide, Tracy Liu, Song Mu, Vincent Ribrag	31
13	Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells 2014 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Daniel Heylmann, Franz Rödel, Thomas Kindler, Bernd Kaina	181
14	Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies 2013 ·Leukemia ·Daniel J. DeAngelo, Andrew Spencer, Kapil N. Bhalla, H. Miles Prince, Thomas Fischer, Thomas Kindler, Frank Giles, Jeffrey W. Scott, Kathryn Parker, (unknown), Margaret M. Woo, Peter Atadja, Kaushal Mishra, Oliver G. Ottmann	116
15	STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2 2012 ·Cancer Research ·Winnie F. Tam, Patricia S. Hähnel, Andrea Schüler, Benjamin H. Lee, Rachel Okabe, Nan Zhu, (unknown), Glen Raffel, Thomas Mercher, Gerlinde Wernig, Ernesto Bockamp, Daniel Sasca, Andreas Kreft, Gertraud W. Robinson, Lothar Hennighausen, D. Gary Gilliland, Thomas Kindler	26
16	JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies 2011 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Andreas Kreft, Thomas Kindler, Erik Springer, C. James Kirkpatrick	2
17	Bioassays to Monitor Taspase1 Function for the Identification of Pharmacogenetic Inhibitors 2011 ·PLoS ONE ·Shirley K. Knauer, Verena Fetz, (unknown), (unknown), Bettina Hofmann, (unknown), (unknown), (unknown), (unknown), Eckhard Thines, Thomas Kindler, Gisbert Schneider, Rolf Marschalek, Roland H. Stauber, Carolin Bier	20
18	PANOBINOSTAT HAS ACTIVITY IN TREATMENT-REFRACTORY HODGKIN LYMPHOMA 2009 ·(unknown), Andrew Spencer, Oliver G. Ottmann, (unknown), Thomas Kindler, Kapil N. Bhalla, (unknown), (unknown), (unknown), (unknown), Edward Ashton, (unknown), Glen Laird, (unknown), H. Miles Prince	3
19	Cross-Inhibition of Interferon-Induced Signals by GM-CSF Through a Block in Stat1 Activation 2007 ·Journal of Interferon & Cytokine Research ·Stefan Kasper, Thomas Kindler, (unknown), Frank Breitenbuecher, Frank D. Böhmer, Christoph Huber, Thomas Fischer	13
20	BCR-ABL as a target for novel therapeutic interventions 2002 ·Expert Opinion on Therapeutic Targets ·Thomas Kindler, (unknown), Thea Kølsen Fischer	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact